Summary Human diploid fibroblasts grow normally in medium containing physiological concentrations of the naturally occurring dipeptide carnosine (fi-alanyl-L-histidine). These concentrations are cytotoxic to transformed and neoplastic cells lines in modified Eagle medium (MEM), whereas these cells grow vigorously in Dulbecco's modified Eagle medium (DMEM) containing carnosine. This difference is due to The dipeptide carnosine (fl-alanyl-L-histidine) is widely distributed in mammalian tissues. It is synthesised by carnosine synthetase from its component amino acids and degraded by carnosinase. There have been many theories about its biological function, but none have been substantiated (reviewed by Quinn et al., 1992, and see Discussion). We previously showed that normal diploid human fibroblasts can grow in high concentrations of carnosine (20 mM-50 mM). Moreover, carnosine treatment can extend the lifespan of these cells and prevent the appearance of the usual signs of late-passage senescence (McFarland and Holliday, 1994) . In the course of these studies we also observed that transformed rodent cell lines, such as 3T3 or CHO, were inhibited by concentrations of carnosine which did not affect diploid cells. This effect was media-dependent, in particular, it was evident that carnosine inhibition of transformed cells was clearly seen in standard MEM (minimum essential medium), but not in DMEM (Dulbecco's modification of MEM). We have followed up these preliminary studies with more detailed investigations of the effects of carnosine on transformed or tumour cell lines and have demonstrated a strong interaction between carnosine and pyruvate. In the absence of pyruvate, physiological concentrations of carnosine are cytotoxic to these cells, but cell growth is normal in medium containing both carnosine and pyruvate. We have used carnosine as a selective agent which can eliminate HeLa cells from a mixed population of these and diploid human fibroblasts.
The dipeptide carnosine (fl-alanyl-L-histidine) is widely distributed in mammalian tissues. It is synthesised by carnosine synthetase from its component amino acids and degraded by carnosinase. There have been many theories about its biological function, but none have been substantiated (reviewed by Quinn et al., 1992, and see Discussion). We previously showed that normal diploid human fibroblasts can grow in high concentrations of carnosine (20 mM-50 mM). Moreover, carnosine treatment can extend the lifespan of these cells and prevent the appearance of the usual signs of late-passage senescence (McFarland and Holliday, 1994) . In the course of these studies we also observed that transformed rodent cell lines, such as 3T3 or CHO, were inhibited by concentrations of carnosine which did not affect diploid cells. This effect was media-dependent, in particular, it was evident that carnosine inhibition of transformed cells was clearly seen in standard MEM (minimum essential medium), but not in DMEM (Dulbecco's modification of MEM). We have followed up these preliminary studies with more detailed investigations of the effects of carnosine on transformed or tumour cell lines and have demonstrated a strong interaction between carnosine and pyruvate. In the absence of pyruvate, physiological concentrations of carnosine are cytotoxic to these cells, but cell growth is normal in medium containing both carnosine and pyruvate. We have used carnosine as a selective agent which can eliminate HeLa cells from a mixed population of these and diploid human fibroblasts.
Materials and methods

Cell lines
The permanent cell lines used are listed in Table I. A549 and  TE85 were kindly provided by Dr Roger Reddel (Children's Medical Research Institute, Westmead Hospital, Sydney, Australia), BL-17/23a and PC3 by Dr Pam Russell (Oncology Research Centre, University of New South Wales, Australia) and WEHI 164 by Dr Larissa Belov (Peptide Technology, Sydney, Australia). Normal MRC-5 and HFF-1 fibroblasts were also used (see McFarland and Holliday, 1994) .
Cell culture
Three basic media were used: MEM, DMEM and RPMI, all from Gibco. Media were supplemented with 10% fetal calf serum (FCS), with 60 Mg ml-' penicillin and 100 jMg ml-' streptomycin. MEM was supplemented with non-essential amino acids (NEA) from Cytosystems. Dialysed FCS was prepared as follows: Spectra/Por membrane tubing (MW cutoff 6000-8000) was cut into lengths and boiled with three changes of distilled water. Aliquots of 20 ml FCS were put into each tube and dialysed overnight against 11 of Hanks' balanced salt solution at 4°C. This was repeated five times. The serum was sterilised by filtration.
Cells were grown in 25 cm2 flasks or in 24-well trays and incubated at 37°C with 5% carbon dioxide. Cells were harvested with trypsin/versene (T/V), and single cell suspensions were counted with a ZF6 Coulter counter. Short-term growth experiments with HeLa cells or other cells were carried out as follows: 104 cells were inoculated into 1 ml medium per well in 24-well trays; cells were counted after 3-4 and 5-7 days by washing with phosphate-buffered saline (PBS), adding 0.2 ml T/V followed by 0.8 ml of MEM with complete dispersal of cells with a 1 ml Gilson pipette.
To determine cell survival CHO cells were grown in MEM with 10% dialysed FCS, 1 mM proline with different concentrations of carnosine. Either 104 cells were added to 1 ml of medium in 24-well trays or 3 x 104 cells were added to 3 ml of medium in 35 mm dishes. After 24 h incubation, the attached cells were trypsinised and plated at appropriate dilutions in 10 ml of MEM in 90 mm dishes. Colonies were stained with Giemsa after 7 days.
HeLa cells were treated in the same way except for the substitution of 1 mM serine for proline. Trypsinised cells were serially diluted in 24-well trays, each well containing 1 ml MEM. Colonies were grown for 6-7 days, stained with Giemsa and counted with an inverted microscope. Colonies of < 10 cells were not counted (see Results section). Figure 2 . However, the difference between FCS and dialysed FCS cannot be solely attributed to pyruvate in the former. A direct assay showed that pyruvic acid in FCS was 1.84 ,ug Further experiments demonstrated the importance of nonessential amino acids (NEA). The HeLa cell line used in these experiments grows very slowly in MEM with 10% dialysed FCS without NEA, but the addition of 1 mM serine or 1 mM glycine (which are components of NEA) allows normal growth. It was also discovered that the interaction of carnosine and pyruvate was strongly affected by alanine or glutamic acid (as sodium glutamate) which are present in NEA. In the presence of 1 mM alanine, approximately 0.5 mM pyruvate allows normal growth of HeLa cells in 20 mM carnosine (Figure 2 ). However, in the absence of alanine, 2 mM pyruvate is required for normal growth (results not shown). Glutamate has a very similar effect to alanine, but the other components of NEA did not interact with pyruvate. We conclude from these experiments that the interactions of low molecular weight components of serum, especially pyruvate and amino acids such as alanine and glutamate, account for the differences between FCS and dialysed FCS which we have documented. In the absence of pyruvate, the strongest toxic affect of carnosine on HeLa cells is seen in MEM lacking NEA, and supplemented with 1 mM serine and 10% dialysed FCS. The cells grow slowly in 10 mM carnosine and are completely inhibited by 15 mM or higher concentrations.
Although the differences between MEM and DMEM containing carnosine are largely due to pyruvate, there is also some effect of glucose. Carnosine is more inhibitory in MEM which has 0.1% glucose, than MEM containing 0.45% glucose, which is the concentration in DMEM (results not shown).
Effects of carnosine on other transformed cell lines As well as MRC-5V1 and HeLa, we have examined MRC-5V2 and four other human cancer cell lines, and two rodent cell lines (see Table I ). In some cases RPMI is the Figure 3 . The result strongly suggests that the biological function of L-carnosine is in some way related to its toxicity to tumour cells. This may depend on the metabolism of L-carnosine within the cell and the lack of uptake of D-carnosine. (Martinez et al., 1978) . This complicates the documentation of the cytotoxicity of carnosine. In contrast, pseudo-diploid CHO cells produce uniform rapidly growing colonies. The survival of CHO cells treated with various levels of carnosine for 24 h in MEM containing dialysed FCS and proline is shown in Figure 4 MRC-5 cells were subcultured until they became senescent and then the medium was changed weekly for 6 weeks. In no case did the HeLa cells reappear. In this experiment, the untreated mixed culture grew for only 4 days before it was split and the cells transferred to MEM with dialysed FCS and 20 mM carnosine. In other experiments, the untreated mixed culture was split twice in MEM (12 days growth) and many more HeLa cells were present. To eliminate these cells, more subcultures in MEM with dialysed FCS and 20 mM carnosine were required before the HeLa cells disappeared (usually 5 -6 subcultures). Again, the cells were finally returned to MEM and passaged until senescent.
Discussion
Carnosine is widely distributed in human tissues with the highest level of 20 mM in skeletal muscle (Mannion et al., 1992) . We previously showed that normal human fibroblasts will grow well in standard media containing 20-30 mM carnosine, and more slowly in 50 mM. In the course of these studies we noticed that transformed cells did not grow in MEM containing similar concentrations of carnosine, whereas these cells grew vigorously in the same concentrations in DMEM. We have investigated this difference and extended the study to seven transformed or neoplastic human cell lines and two rodent cell lines. All Figure 6 ). This procedure for the selection of normal cells and selection against neoplastic cells has obvious implications that could be exploited in various ways in future studies in vitro and in vivo.
Pyruvate has a central place in metabolism. It is the end product of anaerobic glycolysis and it is converted to acetyl CoA which is the essential precursor of the tricarboxylic acid (TCA) cycle for the aerobic generation of ATP. Pyruvate also has an important role in amino acid and fatty acid metabolism. Warburg (1930; 1956 ) discovered that tumour cells have elevated glycolytic activity, leading to increased lactic acid production from pyruvate. This is clearly a very general phenomenon in a wide range of tumour cells (Aisenberg, 1961) . Warburg (1930 Warburg ( , 1956 also proposed that tumour cells are defective in aerobic respiration, but many studies have shown that this is not the case (Weinhouse, 1995; Shapot, 1972; Dills, 1993) . Nevertheless, tumour cells depend more heavily on glycolysis than normal cells, although the altered balance between anaerobic and aerobic metabolism is not well understood (see Shapot, 1972; Dills, 1993) .
The key role of pyruvate in metabolism provides a possible explanation of the carnosine toxicity to tumour cells. It has been shown that the terminal amino group of carnosine reacts strongly with aldehyde and keto groups of sugars. This is the Amadori reaction that is involved in the non-enzymic glycosylation of proteins and the subsequent production, via the Maillard reaction, of advanced glycation end products (AGEs, reviewed by Monnier 1988). Carnosine reacts more strongly than lysine with various sugars and it has been suggested that its role in the cell is to act as a competitive inhibitor of non-enzymic glycosylation of proteins (Michaelis et al., 1992; Hipkiss et al., 1994 Hipkiss et al., , 1995 . Furthermore, it has been shown that carnosine reacts rapidly with the triose phosphate sugar intermediates of glycolysis, particularly glyceraldehyde phosphate and dihydroxyacetone phosphate (A Stevens, personal communication) . From experiments with 3H-labelled carnosine, we know that carnosine is taken up from the medium (unpublished results). Our interpretation of its effects on tumour cells is that it depletes glycolysis intermediates, reduces production of pyruvate by glycolysis and therefore reduces the generation of ATP by this anaerobic pathway. The reduced pyruvate would also limit the production of ATP by the TCA cycle. The end result, we propose, is that the cells have insufficient energy for growth and survival. This whole effect is completely reversed by the addition of pyruvate to the medium. Normal cells are much more tolerant of carnosine possibly because they are less dependent on glycolysis for energy supply and can better regulate glycolysis in relation to aerobic respiration. Although we have as yet no direct evidence for our interpretation, it is strongly supported by experiments with another compound which reacts with sugars, known as tenilsetam, (± )-3-(2-thienyl)-2-piperazinone (Munch et al., 1994 ). We have shown that the naturally occurring dipeptide anserine (which is derived from carnosine by the enzymic methylation of histidine) is also effective in inhibiting tumour cells, whereas homocarnosine is without effect. We have also shown that D-carnosine is non-inhibitory, even at 50 mM in the absence of pyruvate, and presume that it is not actively incorporated into cells. We have also examined the effect of TCA cycle components on carnosine inhibition of tumour cells. Oxaloacetate and x-ketoglutarate have an effect comparable to pyruvate, but the other intermediates are inactive in our assay. This result is not obviously explained by uptake or lack of uptake into the mitochondria, but may relate more to the important role of x-ketoglutarate and oxaloacetate, as well as pyruvate, in amino acid metabolism. We have shown that in the absence of alanine and glutamic acid, considerably more pyruvate is necessary to prevent carnosine toxicity, presumably because a proportion of the pyruvate produced by glycolysis is necessary for amino acid and protein synthesis.
We have previously proposed that carnosine may have an important role in cellular homeostasis. It significantly reduces the normal features of senescence of late passage human fibroblasts and may extend their lifespan in population doublings. Part of this effect may be due to the prevention of non-enzymic glycosylation of proteins, but other metabolic effects could also be important. The functions of carnosine would be integrated into normal metabolic processes, but in tumour cells with abnormal metabolism its particular properties appear to be disastrous for the cell, at least in the absence of pyruvate or two TCA intermediates. In his book 'The Glycolysis and Respiration of Tumours' Aisenberg (1961) concludes by suggesting that chemotherapeutic attack on tumour cells could take place through an agent that acted on the limited respiratory enzymes of the neoplastic cell 'or through an agent which attacked the glycolytic mechanism (perhaps on the assumption that the high rate of glycolysis was uniquely necessary for the neoplastic process)'. If this assumption is correct, and carnosine does indeed interfere with glycolysis, then it may have value as a therapeutic agent, especially if this can be combined with treatments which greatly decrease normal levels of pyruvate and related metabolites.
